This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

nilotinib (Tasigna®)

Reference No. 3615

Publication date:

Appraisal information

nilotinib (Tasigna®) 150 mg capsule
nilotinib (Tasigna®) 200 mg capsule

Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 11/06/2018

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, nilotinib (Tasigna®) cannot be endorsed for use within NHS Wales for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase; treatment of paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.
Statement of Advice (SOA)